- Health Spotlight's Mantle Cell Lymphoma Insights
- Posts
- Weekly Spotlight - 09.01.25
Weekly Spotlight - 09.01.25
Bispecific Antibodies Bring New Hope in Treating Lymphoid Malignancies
Liam Ball
January 09, 2025
Community |
Your journey can be a beacon of hope and a source of strength for others in our community. Together, we can build a stronger, more supportive community. Your story matters, and it deserves to be heard. Fill in this form to be featured. |
Latest News
Bispecific antibodies offer a promising treatment for lymphoma, providing hope to patients. These antibodies target specific antigens and have shown effective results with manageable side effects. Numerous trials are ongoing to explore new antigen targets, enhancing options for those with relapsed or refractory lymphoid malignancies.
The TRIANGLE study revealed a surprising improvement in mantle cell lymphoma treatment. Ibrutinib, as an alternative to autologous stem-cell transplantation, enhanced progression-free and overall survival significantly. While ASCT is redundant for most, high-risk patients benefit. These findings emphasise personalised strategies and bring hope for better patient outcomes.
The phase 2 trial tests nemabrutinib's safety and effectiveness in treating various relapsed or refractory non-Hodgkin lymphomas. The trial includes patients with specific lymphoma types across multiple UK locations. Nemabrutinib, a BTK inhibitor, offers hope by targeting resistant mutations, where other treatments fall short.
Professor Kim Tae-min highlights the advancements in bispecific antibodies, notably AZD-0486, in lymphoma care. This drug achieves an 83% complete response rate in follicular lymphoma with manageable side effects. He stresses the importance of clinical trials for access in Korea, amidst high treatment costs.
=
Health Spotlight’s Mantle Cell Lymphoma is a Contentive publication in the Healthcare division